Current Headlines

  1. New Evolution-Busting Drug Overcomes Resistance In Aggressive Breast Cancers

    A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown

  2. I-Mab Biopharma Receives IND Approval In China For Proprietary CD73 Antibody TJD5

    I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its IND application for TJD5, a novel CD73 antibody has been approved by the National Medical Products Administration(NMPA) to initiate clinical trials in patients with advanced solid tumours in China

  3. Verastem Oncology Receives Orphan Drug Designation From FDA For COPIKTRA For The Treatment Of T-Cell Lymphoma

    Verastem, Inc. (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, recently announced duvelisib (COPIKTRATM) has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of T-Cell lymphoma

  4. Goldfinch Bio Announces Licensing Agreement With Takeda For CB1 Monoclonal Antibody For The Treatment Of Rare And Metabolic Kidney Diseases

    Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, recently announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody. Goldfinch Bio will assume all development and commercialization responsibilities for the treatment of rare and metabolic kidney diseases worldwide

  5. FDA Approves Second Drug To Prevent HIV Infection As Part Of Ongoing Efforts To End The HIV Epidemic

    The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex

  6. Viscient Biosciences Proposes Merger To Unlock 3D Bioprinting Potential In Drug Discovery With Organovo

    Viscient Biosciences (“Viscient”), a biotech therapeutics company working at the intersection of 3D tissue technology and transcriptomics technology to discover and develop drugs across a range of therapeutic areas with significant unmet medical need, recently announced that it has formally submitted a merger proposal to Organovo Holdings, Inc.’s (“Organovo”) Board of Directors to combine the two companies

  7. ANI Pharmaceuticals Announces Launch Of Aspirin And Extended Release Dipyridamole Capsules, 25mg/200mg

    ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®). This launch represents ANI's fifth generic product introduction in 2019

  8. Xylyx Bio Announces Development Of Disease-Specific Cell Culture Products To Accelerate Anti-Fibrotic Drug Discovery And Screening

    Xylyx Bio, a pioneer in tissue-specific extracellular matrix biomaterials, today announced the development of substrates for anti-fibrotic drug discovery as the next stage of its pipeline of pre-clinical cell culture products

  9. Clarivate Analytics Introduces Next-Generation Pre-Clinical Drug Research Platform With Cortellis Drug Discovery Intelligence

    Clarivate Analytics plc (NYSE:CCC; CCC.WS), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced it has enhanced its well-established Integrity platform to support pharmaceutical companies' drug discovery and pre-clinical efforts

  10. Evotec And Indivumed Achieve Milestone In Joint Strategic Drug Discovery Collaboration

    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer